Epitalon Dosage: What the Research Used and Why There's No Established Protocol

Search for an Epitalon dose and you'll find confident numbers — almost always something like "5–10 mg per day subcutaneously for 10–20 days, once or twice a year." This page exists to be honest about where those numbers come from, which is: not from any clinical protocol. Epitalon (epithalon) is not an approved drug, has never had a dosing schedule established for any condition, and the modern subcutaneous "mg per day" courses circulating online are extrapolated folk dosing, not validated regimens. What follows is a description of what the actual Russian bioregulator research administered — which looked quite different — and why none of it translates into a number you can safely act on. This is research-only context, not medical advice; the honest first move is a clinician conversation, not a forum protocol. For the wider evidence picture, see our Epitalon overview.

Why "Epitalon dosage" is the wrong question

Epitalon is a synthetic four-amino-acid pineal tetrapeptide (Ala-Glu-Asp-Gly) from the Russian "bioregulator" lineage associated with Vladimir Khavinson and colleagues — the synthetic stand-in for the older pineal preparation epithalamin. A recent overview frames it as a "highly bioactive" pineal tetrapeptide with "promising properties," which is a fair description of where it sits: real bioactivity in models, and a large gap between that and proven clinical benefit¹. You cannot have an established dose for a compound that was never approved, whose effects in living humans were never reliably demonstrated, and whose foundational evidence comes largely from the research lineage that created it³. So the right framing is not "what is the Epitalon dose?" but "what did the older studies happen to administer, and how little that tells you."

What the older bioregulator studies actually used

The human and animal literature on pineal peptides is old, small, and used routes that bear little resemblance to the home subcutaneous shot sold today. The classic work was done with short courses of the peptide preparations — administered in the older studies intramuscularly, and in some pineal-peptide work intranasally — not as a year-round self-injected SC regimen. The most on-brand, sleep-relevant result from this lineage is that pineal peptides were reported to normalize the daily melatonin rhythm in old monkeys and elderly people, the kind of age-related flattening of the melatonin curve that tracks with disrupted sleep timing². But note what that study is and isn't: a circadian-timing signal in older subjects, delivered as a short supervised course in a research setting — not a validated milligram dose, and not a demonstration that a fixed daily SC injection cures insomnia. Khavinson's own summary of the program presents these as short bioregulator courses within a research framework, not as an established consumer dosing protocol³.

Why the online "5–10 mg/day SC" numbers are extrapolation

The injection protocols you'll see online have almost no relationship to what was studied. They convert a vague research course into a fixed milligram-per-day number, switch the route to a subcutaneous home shot, and bolt on a tidy "10–20 days, 1–2× per year" schedule — none of which any controlled trial validated as a dose. Three problems stack up. First, route matters: the older work used intramuscular and intranasal delivery, and there is no published pharmacokinetic study establishing a subcutaneous Epitalon dose, so the SC numbers inherit no PK basis. Second, the underlying human evidence is thin, dated, and largely from the developing lineage — extrapolating it into a confident mg regimen inherits no efficacy data at all³. Third, the precision is false: a "5 mg" instruction implies a validated target where none exists, and even the marquee melatonin-rhythm finding was a short supervised course, not a self-dosed milligram schedule². The honest description of these protocols is folk dosing — numbers that circulate because they circulate, not because they were tested.

The grey-market measuring and sourcing problem

Layered on top of the missing protocol are the practical hazards of any research-only peptide. Epitalon sold "for research use, not for human consumption" carries no guarantee of identity, purity, or actual peptide content — a vial labeled "10 mg" may not contain 10 mg of Epitalon, and the regulatory overview is blunt that this is unapproved material with no oversight of quality¹. Even if the vial were accurate, turning that powder into an injected dose means reconstituting a lyophilized peptide with bacteriostatic water and converting milligrams into units on an insulin syringe — the same arithmetic step where peptide users most often slip by an order of magnitude. We walk through that reconstitution math in storage & reconstitution, and our calculators help with the concentration arithmetic as a planning aid — but no calculator can validate a dose the science never established.

The honest bottom line

There is no established Epitalon dosage because Epitalon is not an approved drug and its effects in humans were never reliably demonstrated. The real bioregulator research used short courses, intramuscular or intranasal, in a supervised research setting — the most on-brand result being a normalized melatonin rhythm in older subjects, not a validated milligram protocol². The "5–10 mg/day subcutaneous for 10–20 days, 1–2× a year" numbers online are extrapolated folk dosing — wrong route, false precision, no efficacy data behind them — compounded by the identity, purity, and measuring uncertainties of grey-market peptides¹. If better sleep is the goal, the evidence-based path is not a self-dosed research peptide: start with our honest look at peptides for sleep, compare the same no-protocol problem in DSIP dosage, and make any peptide decision a clinician-supervised one. Anyone presenting a confident Epitalon dose is selling certainty the science doesn't have.